Jeil Pharma Holdings Inc. (002620) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jeil Pharma Holdings Inc. (002620:KRX), powered by AI.

Current Price
₩7,350
P/E Ratio
8.0
Market Cap
117.4B
Sector
Healthcare
What is the Jeil Pharma Holdings Inc. stock price forecast?

Jeil Pharma Holdings Inc. is currently trading at ₩7,350. View real-time AI analysis on Alpha Lenz.

What is Jeil Pharma Holdings Inc. insider trading activity?

View the latest insider trading data for Jeil Pharma Holdings Inc. on Alpha Lenz.

What is Jeil Pharma Holdings Inc.'s P/E ratio?

Jeil Pharma Holdings Inc.'s P/E ratio is 8.0.

Jeil Pharma Holdings Inc.

KRX · 002620
₩7,350+200(+2.80%)Market closedKRX regular session 09:00–15:30 KST
Ask about Jeil Pharma Holdings Inc.'s future dividend policy...
Alpha Chat Insight

Jeil Pharma Holdings Inc. trades at a P/E of 8.0 (undervalued) with modest ROE of 4.7%.

Ask for details

Company Overview

Jeil Pharma Holdings Inc. is a prominent entity in the pharmaceutical sector, recognized for its comprehensive range of healthcare products and solutions. Primarily, the company focuses on the development, manufacturing, and distribution of pharmaceuticals and medical supplies. This includes prescription medications, over-the-counter drugs, and various healthcare products that cater to a wide array of medical needs. Jeil Pharma Holdings plays a significant role in the healthcare industry by advancing medical research and enhancing public health outcomes. With its robust product portfolio, the company impacts both local and global markets by addressing critical therapeutic areas such as cardiology, neurology, and infectious diseases. The strategic position of Jeil Pharma Holdings in the market is further bolstered by its commitment to quality, innovation, and compliance with global healthcare standards. By leveraging advanced technologies and expanding its research capabilities, the company aims to contribute significantly to the progress of medical science and improve accessibility to essential healthcare products.

CEO한상철
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees37

Company Statistics

FY 2025

Profile

₩117,404,159,250Market Cap
₩657,614,014,070Revenue
15.97MShares Out
37Employees

Margins

38.55%Gross
9.23%EBITDA
5.93%Operating
5.99%Pre-Tax
5.27%Net

Valuation

8.02P/E
0.37P/B
0.18EV/Sales
6.24EV/EBITDA
-13.14P/FCF

Growth (CAGR)

-6.05%Rev 3Yr
-2.90%Rev 5Yr
N/AOp Inc 3Yr
11.64%Op Inc 5Yr
N/ANet Inc 3Yr
18.32%Net Inc 5Yr

Returns

3.92%ROA
4.68%ROE
5.30%ROIC

Financial Health

₩56,189,279,220Cash & Cash Equivalents
₩351,358,012,900Net Debt
86.88%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Jeil Pharma Holdings Inc. (ticker: 002620) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 37 employees. Market cap is $117.4B.

The current price is ₩7,350 with a P/E ratio of 8.02x and P/B of 0.37x.

ROE is 4.68% and operating margin is 5.93%. Annual revenue is $657.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Jeil Pharma Holdings Inc. (002620) Stock Forecast 2026 ₩7,350 — Price, Financials & Analyst Targets | Alpha Lenz